18F-Fluorodihydroxyphenylalanine PET/CT in Patients with Neuroendocrine Tumors of Unknown Origin: Relation to Tumor Origin and Differentiation

Alessio Imperiale1,2, Edmond Rust1, Sophie Gabriel1, Julien Detour1, Bernard Goichot5, Bernard Duclos6, Jean-Emmanuel Kurtz7, Philippe Bachellier8, Izzie-Jacques Namer1,2, and David Taieb3

1Biophysics and Nuclear Medicine, Hautepierre University Hospital, Strasbourg, France; 2ICube, University of Strasbourg/CNRS (UMR 7357) and FMTS, Faculty of Medicine, Strasbourg, France; 3Nuclear Medicine, La Timone University Hospital, European Center for Research in Medical Imaging, Aix-Marseille University, Provence, France; 4Radiopharmacy, Hautepierre University Hospital, Strasbourg, France; 5Internal Medicine, Hautepierre University Hospital, Strasbourg, France; 6Gastroenterology, Hautepierre University Hospital, Strasbourg, France; 7Oncology, Hautepierre University Hospital, Strasbourg, France; and 8Visceral Surgery and Transplantation, Hautepierre University Hospital, Strasbourg, France

This work was performed to evaluate the performance of 18F-fluorodihydroxyphenylalanine (18F-FDOPA) PET/CT in detecting primary neuroendocrine tumors (NETs) occult on morphologic and functional imaging, in relation to tumor origin and differentiation. Methods: A retrospective study of NET patients who were investigated with 18F-FDOPA PET/CT imaging in 2 academic endocrine tumor centers was conducted. Only patients with negative conventional and somatostatin receptor scintigraphy (SRS) results were studied. Results: Twenty-seven patients were evaluated with 18F-FDOPA PET/CT, 23 at their initial staging and 4 during their follow-up. The primary occult NET was localized by 18F-FDOPA PET/CT in 12 patients (overall sensitivity, 44%; 52% in patients evaluated at initial diagnosis), leading to tumor resection in all cases. The primary tumors were distributed and graded as follows: 1 duodenum G2 lesion, 7 ileum G2 lesions, 2 terminal ileum G1 lesions, 1 pancreas G2 lesion, and 1 gallbladder G3 lesion. Patients with positive 18F-FDOPA PET/CT results had higher values of serum chromogranin A (100% vs. 20%, P = 0.0003), serotonin, or urinary 5-hydroxyindolacetic acid (83% vs. 20%, P = 0.003). Two false-negative results were related to poorly differentiated duodenal and prostatic NETs (G3). 18F-FDOPA PET/CT showed more metastatic anatomic regions than SRS in 17 patients. Conclusion: 18F-FDOPA PET appears to be a sensitive functional imaging tool for the detection of primary NETs occult on SRS, especially tumors with a well-differentiated pattern and serotonin secretion.

Key Words: neuroendocrine; unknown primary tumor; somatostatin receptor scintigraphy; 18F-FDOPA; PET/CT

DOI: 10.2967/jnumed.113.126896

N euroendocrine tumors (NETs) are epithelial neoplasms derived from cells of the diffuse neuroendocrine system. Their incidence is usually reported as 40–50 cases per million individuals, accounting for about 0.5% of all cancers in the adult population (1). NETs can be classified as functioning or nonfunctioning according to the presence or absence of tumoral secretion of peptides or hormones. In about 20%–50%, the primary tumor is of unknown origin, accounting for 2%–4% of all carcinomas of unknown primary origin (2–6). The identification of the primary tumor is crucial in treatment planning since resection of the primary tumor is associated with improvement of symptom-free survival, overall survival, and quality of life even at later stages of the disease with presence of distant metastases (7–10). Furthermore, the detection of a primary tumor of pancreatic origin enables the use of new, highly efficient molecular targeted therapies such as everolimus (an inhibitor of mammalian target of rapamycin) and sunitinib (an angiogenic agent) (11,12).

A multimodality imaging approach is usually needed to fully evaluate the extent of disease and to localize the primary tumor. Nevertheless, the primary tumor frequently remains occult on the recommended morphologic and functional imaging studies based on the use of multiphasic CT, MR imaging, endoscopic sonography, and somatostatin receptor scintigraphy (SRS) (2,13,14).

In recent years, dihydroxyphenylalanine radiolabeled with 18F (18F-FDOPA) has been developed to image NETs originating in different areas (15,16). The uptake and retention of 18F-FDOPA is dependent on the expression of the large neutral amino acid transporter system and the activity of amino acid decarboxylase (17). It is widely recognized that the sensitivity of 18F-FDOPA is influenced by the embryologic origin of the NETs, with a higher sensitivity for midgut NETs than for others (18,19).

Analysis of the relevant literature is hampered by the frequent mixing of different clinical situations. Moreover, patients with NETs of unknown origin are rarely investigated in a specific manner. Reported sensitivities for 18F-FDOPA PET and PET/CT in the detection of primary NETs have ranged from 29%–100% (19–23), and sensitivity for SRS-negative lesions has scarcely been investigated. It is therefore important to specifically evaluate the diagnostic performance of 18F-FDOPA PET in the detection of primary NETs.

The aim of the present retrospective study was to evaluate the performance of 18F-FDOPA PET/CT in the detection of neuroendocrine primary tumors in a cohort of patients with negative findings on conventional imaging and SRS.
MATERIALS AND METHODS

Patient Population

Among all the patients evaluated by 18F-FDOPA PET/CT between January 2009 and December 2012 in the Nuclear Medicine Department of the university hospitals of Strasbourg and Marseille, only patients with histologically proved metastatic disease of neuroendocrine origin were evaluated. Tumors were classified for differentiation and grade according to the criteria of the World Health Organization and the European Neuroendocrine Tumour Society (24,25). Imaging work-up included at least liver sonography, triphasic thoracoabdominal CT, abdominal MR imaging, and SRS performed less than 3 mo before the 18F-FDOPA PET/CT. Follow-up data were obtained for at least 12 mo after 18F-FDOPA PET/CT in surviving patients.

All selected subjects underwent a standard physical examination investigating the presence of symptoms related to tumoral secretion, particularly flushing and diarrhea. Serum chromogranin A, serum serotonin, and urinary 5-hydroxyindolacetic acid were measured in all patients. Serum gastrin, insulin, glucagon, and ACTH were measured only in selected patients. In addition to the conventional imaging work-up, endoscopic sonography combined with fine-needle aspiration cytology or large-bowel colonoscopy, video capsule endoscopy, or 18F-FDG endoscopic sonography combined with fine-needle aspiration cytology only in selected patients. In addition to the conventional imaging work-up, particularly flushing and diarrhea. Serum chromogranin A, serum investigating the presence of symptoms related to tumoral secretion,

Technical Features and Interpretation Criteria for SRS and PET/CT

SRS included anterior and posterior whole-body planar images (matrix, 256 × 1,024; speed, 8–10 cm/min), and abdominopelvic SPECT/CT (21 patients) or abdominopelvic SPECT (6 patients) was performed and 24 h after intravenous injection of 148–259 MBq (4–7 mCi) of 111In-pentetreotide using a 2-head SPECT/CT (21 patients) or abdominopelvic SPECT (6 patients) was used for a limited number of patients. 18F-FDG PET/CT was added to the work-up for selected patients with occult primary NETs on 18F-FDG PET/CT, poorly differentiated NETs, or a Ki-67 of at least 15%.

18F-FDOPA was used in the setting of marketing authorization. The Institutional Review Board approved this retrospective study, and the requirement to obtain written informed consent was waived.

RESULTS

Patients and Tumors

Twenty-seven patients were eligible for final analysis. There were 16 men (59%) and 11 women, with a mean age of 60 y (range, 25–76 y). Twenty-three patients underwent 18F-FDOPA PET/CT for initial staging and the remaining 4 patients for follow-up during therapy, which consisted of chemotherapy in 3 patients and peptide-receptor radiotherapy in 1 patient. NET was diagnosed from pathologic analysis of liver metastases in 19 patients (70%), retroperitoneal or mesenteric lymph node metastases in 6 patients (22%), upper- and lower-lymph node metastases in 2 patients (7%), peritoneal carcinomatosis in 2 patients (7%), adrenal metastasis in 1 patient (4%), and lung metastasis in 1 patient (4%). NETs were classified as well differentiated and poorly differentiated in, respectively, 23 patients (85%) and 4 patients (15%), and tumor stages were G1, G2, and G3 in 5 patients (18%), 18 patients (67%), and 4 patients (15%), respectively (24,25). Most patients (20/27 [74%]) had clinical symptoms consisting of a variable association of diarrhea (55%), flushing (40%), abdominal pain (15%), anorexia (15%), and weight loss (40%). Serum chromogranin A was elevated in 17 patients (63%). Moreover, both serum serotonin and urinary 5-hydroxyindolacetic acid values were elevated in 13 patients (48%).

18F-FDOPA PET/CT Findings for Localization of Primary Tumor

Among the 27 selected patients with negative SRS results, 18F-FDOPA PET/CT successfully detected the primary tumor with subsequent histologic confirmation in 12 patients (overall sensitivity, 44%; 52% in patients evaluated at initial diagnosis). According to tumor differentiation, the sensitivity of 18F-FDOPA PET/CT for detection of the primary tumor was 48% (11/23 patients) and 25% (1/4 patients) in patients with well differentiated and poorly differentiated NET metastases, respectively.

More patients with positive 18F-FDOPA PET/CT results than patients with negative results were symptomatic (100% vs. 53%,
and had higher values of serum chromogranin A (100% vs. 20%, \( P = 0.0003 \)), serotonin, or urinary 5-hydroxyindolacetic acid (83% vs. 20%, \( P = 0.003 \)).

The primary tumors detected by \(^{18}\)F-FDOPA PET/CT were distributed and graded as follows: 1 duodenum G2 lesion, 7 ileum G2 lesions, 2 terminal ileum G1 lesions, 1 pancreas G2 lesion, and 1 gallbladder G3 lesion. The Ki-67 index ranged from 1% to 60% and was always equal to or higher than its metastatic counterpart.

All primary tumors were detected on whole-body images (Fig. 1). The single primary pancreatic NET (patient 6) was visible despite a faint and homogeneous \(^{18}\)F-FDOPA uptake in the whole pancreas. In 2 patients, \(^{18}\)F-FDOPA PET/CT showed prostatic uptake, which was considered unrelated to the NET disease. Histologic analysis was available for 1 patient and showed nonspecific inflammation. Two false-negative results were related to duodenal and prostatic poorly differentiated NETs (G3) (patients 8 and 3). In 13 patients, the primary tumor was not detected within a mean follow-up of 21 mo (range, 12–32 mo) after PET imaging. In the latter case, the patient died 2 mo after PET imaging from his poorly differentiated NET without identification of the primary NET.

\(^{18}\)F-FDG PET/CT was performed on 10 patients and was positive in only 1 patient with a poorly differentiated biliary NET (patient 12).

Patient and tumor characteristics and PET/CT findings are detailed in Table 1

\(^{18}\)F-FDOPA PET/CT Metastatic Disease Assessment and Clinical Impact

The comparison between \(^{18}\)F-FDOPA PET/CT and SRS showed a concordant pattern in 8 patients (30%) and discordant results in the remaining 19 (70%). \(^{18}\)F-FDOPA PET/CT showed more localizations than did SRS in 17 patients. Additional lesions were localized as follows: upper diaphragmatic lymph nodes in 12 patients (71%), lower diaphragmatic lymph nodes in 12 patients (71%), liver in 5 patients (29%), bone in 3 patients (18%), and peritoneal carcinomatosis in 1 patient (6%). In the additional discordant situations, SRS showed liver metastases that were occult on \(^{18}\)F-FDOPA PET/CT in 2 patients. Serotonin immunoexpression analysis performed on liver tissue samples was negative in these 2 patients. The primary NET remained occult on both functional imaging modalities in the subsequent follow-up.

If resection of the primary tumor based on \(^{18}\)F-FDOPA PET/CT findings is considered to be a major clinical impact, \(^{18}\)F-FDOPA PET/CT induced a major modification in the therapeutic strategy in 12 (44%) of the 27 patients included. None of the patients who underwent surgery for their primary NET had a false-positive lesion.

DISCUSSION

The present study determined the sensitivity of \(^{18}\)F-FDOPA PET/CT in the detection of primary NETs in a large cohort of patients with negative morphologic and functional imaging results. In our series, the sensitivity of \(^{18}\)F-FDOPA PET/CT was 44% overall and increased to 52% in patients evaluated at initial diagnosis. Furthermore, \(^{18}\)F-FDOPA PET/CT detected more of the involved anatomic regions than did SRS in 17 patients.

Localization of the primary NET remains a diagnostic challenge in different clinical situations such as gastroenteropancreatic tumors, hyperinsulinism, and paraneoplastic Cushing syndrome (2,13,14). To date, only a few studies have evaluated the clinical value of \(^{18}\)F-FDOPA PET/CT in NETs (20–23), probably because \(^{18}\)F-FDOPA is not routinely available at most imaging centers worldwide. The overall reported sensitivity of \(^{18}\)F-FDOPA PET/CT ranged from 29% to 100% (19–23), but results on the detection of the primary tumor have only rarely been specifically addressed (26,27). Hoegerle et al. (20) were the first to uniquely demonstrate the utility of \(^{18}\)F-FDOPA PET to localize gastroenteropancreatic tumors. They found 88% sensitivity for \(^{18}\)F-FDOPA PET in a series of 8 patients with NETs of unknown origin, with a higher detection rate than SRS (50%) and \(^{18}\)F-FDG (25%). In 2006, Montravers et al. compared SRS and \(^{18}\)F-FDOPA PET/CT in 30 patients with metastatic NETs (21). \(^{18}\)F-FDOPA PET/CT detected the unknown primary lesion in only 2 of 7 patients (29%). In another study by the same group, the primary NET was detected by \(^{18}\)F-FDOPA PET/CT in 6 of 16 patients (22). In these 2 studies, \(^{18}\)F-FDOPA PET/CT was more sensitive than SRS in patients with secreting carcinoid tumors. In contrast, SRS was superior to \(^{18}\)F-FDOPA PET/CT in noncarcinoid tumors. In our series, as in others, the sensitivity of \(^{18}\)F-FDOPA was clearly influenced by the embryologic origin of the NETs and their tumor differentiation. The detection rate of the primary tumor by \(^{18}\)F-FDOPA PET/CT was higher in well-differentiated NETs of the mid gut. This higher value of \(^{18}\)F-FDOPA PET/CT over SRS is probably related to an increased sensitivity of PET/CT cameras over SPECT/CT cameras and to specific features such as overexpression or increased activity of the amino acid decarboxylase involved in the biosynthesis of serotonin. Fiebrich et al. showed that the whole-body metabolic tumor burden correlates with the amount of serotonin secretion (28).

FIGURE 1. SRS anterior whole-body planar imaging (A), \(^{18}\)F-FDOPA PET/CT (anterior maximum-intensity projection) (B), axial SRS SPECT/CT (C), and axial \(^{18}\)F-FDOPA PET/CT (D) performed on a 56-y-old patient (patient 17) with metastatic NET of unknown origin. \(^{18}\)F-FDOPA PET/CT confirmed presence of liver metastases and identified primary tumor in ileum (arrow), occult on both conventional imaging and SRS.
<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Sex</th>
<th>Age (y)</th>
<th>Clinical symptoms and signs</th>
<th>Tumor markers</th>
<th>Diagnosis of NET (histology)</th>
<th>Treatment before PET/CT</th>
<th>PET/CT findings</th>
<th>Differentiation and grade (metastasis)</th>
<th>Differentiation and grade (primary)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>56</td>
<td>None</td>
<td></td>
<td>Liver metastases</td>
<td>None</td>
<td>W 2 1</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>76</td>
<td>Weight loss, diarrhea</td>
<td>+ + +</td>
<td>Liver metastases</td>
<td>Chemo</td>
<td>W 3 2</td>
<td>N</td>
<td>Unknown</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>62</td>
<td>None</td>
<td></td>
<td>Upper clavicular LN metastasis</td>
<td>None</td>
<td>W 2 1</td>
<td>N</td>
<td>Unknown</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>69</td>
<td>None</td>
<td></td>
<td>Adrenal metastasis</td>
<td>None</td>
<td>W 20 2</td>
<td>N</td>
<td>Unknown</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>69</td>
<td>Weight loss, flushing</td>
<td>+ + +</td>
<td>Liver metastases</td>
<td>None</td>
<td>W 3 2</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>58</td>
<td>Weight loss</td>
<td></td>
<td>Liver metastases</td>
<td>None</td>
<td>W 5 2</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>68</td>
<td>None</td>
<td></td>
<td>Liver metastases</td>
<td>None</td>
<td>W 3 2</td>
<td>N</td>
<td>Unknown</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>55</td>
<td>Weight loss, anorexia</td>
<td></td>
<td>Liver metastases</td>
<td>None</td>
<td>W 10 2</td>
<td>N</td>
<td>Unknown</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>56</td>
<td>Weight loss, anorexia</td>
<td></td>
<td>Liver metastases, peritoneal carcinomatosis</td>
<td>Chemo + MRT</td>
<td>W 15 2</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>66</td>
<td>None</td>
<td></td>
<td>Upper clavicular LN metastasis</td>
<td>None</td>
<td>P 40 3</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>65</td>
<td>Weight loss, flushing</td>
<td></td>
<td>Lung and liver metastases</td>
<td>Chemo</td>
<td>P 35 3</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>50</td>
<td>Abdominal pain</td>
<td></td>
<td>Liver metastases</td>
<td>None</td>
<td>P 60 3</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>48</td>
<td>None</td>
<td></td>
<td>Liver metastases</td>
<td>Chemo</td>
<td>W 3 2</td>
<td>N</td>
<td>Unknown</td>
</tr>
<tr>
<td>14</td>
<td>F</td>
<td>69</td>
<td>None</td>
<td></td>
<td>Retropertitoneal LN metastasis</td>
<td>None</td>
<td>W 3 2</td>
<td>N</td>
<td>Unknown</td>
</tr>
<tr>
<td>15</td>
<td>M</td>
<td>58</td>
<td>Anorexia</td>
<td></td>
<td>Liver metastases</td>
<td>None</td>
<td>P 20 3</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>16</td>
<td>M</td>
<td>40</td>
<td>Weight loss, diarrhea</td>
<td>+ + +</td>
<td>Liver metastases</td>
<td>None</td>
<td>W 2 1</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>17</td>
<td>M</td>
<td>55</td>
<td>Flushing, diarrhea</td>
<td>+ + +</td>
<td>Liver metastases</td>
<td>None</td>
<td>W 5 2</td>
<td>Y</td>
<td>Ileum</td>
</tr>
<tr>
<td>18</td>
<td>M</td>
<td>49</td>
<td>Flushing, diarrhea</td>
<td>+ + +</td>
<td>Mesenteric LN metastases</td>
<td>None</td>
<td>W 3 2</td>
<td>Y</td>
<td>Ileum</td>
</tr>
<tr>
<td>19</td>
<td>M</td>
<td>64</td>
<td>Flushing, diarrhea</td>
<td>+ + +</td>
<td>Retropertitoneal and mesenteric LN metastasis</td>
<td>None</td>
<td>W 5 2</td>
<td>N</td>
<td>Unknown</td>
</tr>
<tr>
<td>20</td>
<td>M</td>
<td>64</td>
<td>Abdominal pain</td>
<td></td>
<td>Intestinal occlusion secondary to peritoneal carcinomatosis</td>
<td>None</td>
<td>W 15 2</td>
<td>N</td>
<td>Unknown</td>
</tr>
<tr>
<td>21</td>
<td>M</td>
<td>66</td>
<td>Weight loss, diarrhea</td>
<td>+ + +</td>
<td>Liver metastases</td>
<td>None</td>
<td>W 3 2</td>
<td>Y</td>
<td>Ileum</td>
</tr>
<tr>
<td>22</td>
<td>M</td>
<td>66</td>
<td>Diarrhea</td>
<td></td>
<td>Liver metastases</td>
<td>None</td>
<td>W 5 2</td>
<td>Y</td>
<td>Ileum</td>
</tr>
<tr>
<td>23</td>
<td>F</td>
<td>69</td>
<td>Flushing, diarrhea</td>
<td>+ + +</td>
<td>Retropertitoneal LN and liver metastasis</td>
<td>None</td>
<td>W 3 2</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>24</td>
<td>M</td>
<td>75</td>
<td>Flushing, diarrhea</td>
<td>+ + +</td>
<td>Liver metastases</td>
<td>None</td>
<td>W 1 1</td>
<td>Y</td>
<td>Terminal ileum</td>
</tr>
</tbody>
</table>
Accurately localizing NETs plays a critical role in the management of patients with these tumors, especially in determining surgery of the primary tumors (20–23). In our series, 12 patients underwent surgery based on 18F-FDOPA PET/CT findings.

Several hypotheses may explain the decrease of 18F-FDOPA PET/CT in noncarcinoid tumors. One hypothesis is that there is a specific imaging phenotype related to the absence of activation of the large neutral amino acid transporter and CD98 transporter systems. It is well established that these tumors exhibit specific responses to targeted therapies, and this molecular singularity may also extend to functional imaging. However, this possibility remains speculative and requires evaluation in further basic science research.

Another explanation may be related to the imaging protocol itself, which may be inappropriate for optimal detection of these tumors. It has been reported that the high physiologic 18F-FDOPA uptake by the whole pancreas potentially reduces the detection rate of pancreatic tumors (29). The use of carbidopa before 18F-FDOPA injection for inhibiting amino acid decarboxylase increases the signal-to-background ratio (30,31), but negativization of 18F-FDOPA focal pancreatic hot spots has been reported after carbidopa in patients with hyperinsulinemic hypoglycemia.

At present, no recommendation exists concerning the use of carbidopa premedication, but this approach should be further evaluated in this clinical setting as well as the optimal timing for image acquisition.

We acknowledge several limitations to our study: its retrospective design, the limited number of patients, and the short duration of follow-up. However, to our knowledge it is the largest study showing extensive data related to primary tumors.

On the basis of the currently available imaging techniques for diagnosis and staging of NETs, we propose that 18F-FDOPA PET/CT be performed as the first-line functional imaging technique for NETs of unknown origin, especially those with a well-differentiated tumor and serotonin secretion. SRS should be reserved for other situations or when 18F-FDOPA PET/CT findings are negative for a primary tumor or targeted radiotherapy is planned.

The current leading role of 18F-FDOPA PET/CT in the evaluation of NETs will need to be further compared with newly introduced and promising agents for PET imaging such as somatostatin analogs labeled with 68Ga (32). High sensitivity has been reported for PET/CT with 68Ga-labeled peptides in patients with clinically, biochemically, or radiologically suspected NET (33–35). Recently, some authors prospectively compared 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT in the same patients with gastroenteropancreatic tumor NETs and highlighted the high diagnostic sensitivity of 68Ga-DOTANOC to assess the extent of metastatic disease (36). Moreover, 68Ga-DOTANOC PET/CT seems to be a promising diagnostic modality for detecting primary tumor in patients with neuroendocrine carcinoma of unknown origin (37). At present, only few clinical investigations involving a limited number of patients with NET have compared the diagnostic role of PET/CT with 18F-FDOPA or 68Ga-labeled somatostatin analogs (38,39). 68Ga-DOTANOC PET/CT was found to be more accurate than 18F-FDOPA PET/CT in the detection of primary tumor and metastatic disease. Unfortunately, the heterogeneity of the studied population still represents a major bias for a reliable head-to-head comparison of the imaging approaches.

CONCLUSION

18F-FDOPA PET appears to be a sensitive functional imaging tool for the detection of primary NETs occult on SRS. Some
unanswered questions arise from lesions missed by 18F-FDOPA PET, including specific genetic or molecular features and the possibility of inappropriate acquisition protocols.

DISCLOSURE

The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734. No potential conflict of interest relevant to this article was reported.

REFERENCES


5. Kwkekeboom DJ, Krenning EP, Lebtahi R, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumours: peptide receptor radionuclide therapy. with 18 USC section 1734. No potential conflict of interest relevant to this article was reported.


18F-Fluorodihydroxyphenylalanine PET/CT in Patients with Neuroendocrine Tumors of Unknown Origin: Relation to Tumor Origin and Differentiation

Alessio Imperiale, Edmond Rust, Sophie Gabriel, Julien Detour, Bernard Goichot, Bernard Duclos, Jean-Emmanuel Kurtz, Philippe Bachellier, Izzie-Jacques Namer and David Taleb

Published online: December 16, 2013.
Doi: 10.2967/jnumed.113.126896

This article and updated information are available at: http://jnm.snmjournals.org/content/55/3/367

Information about reproducing figures, tables, or other portions of this article can be found online at: http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at: http://jnm.snmjournals.org/site/subscriptions/online.xhtml